We examined clinical outcomes for 53 young infants (<3 months of age) treated with outpatient parenteral antimicrobial therapy after discharge from a freestanding children's hospital. None of the patients experienced treatment failure or disease progression; 9% of them experienced a catheter-related complication, but this percentage is not different than that for older children.
Outpatient parenteral antimicrobial therapy (OPAT) is the intravenous administration of antimicrobial agents in an ambulatory setting. OPAT has been used successfully in children for decades to treat infections that require long-term management. The major advantages of OPAT over prolonged hospitalization are lower cost and earlier return to the home environment, which improves patient and caregiver quality of life. However, OPAT complications occur frequently and can include thrombosis, accidental dislodgement, and central-line-associated infection [1] [2] [3] [4] . Results of previous studies indicate that peripherally inserted central catheter (PICC) complications occur in up to 30% of pediatric patients [5] , and younger age has been suggested as a possible risk factor for such complications [4, 5] .
Despite the fact that OPAT is used widely in pediatrics, the number of published reports that describe OPAT use for young infants (ie, less than 3 months old) have been limited [6, 7] . Data are especially limited for infants <1 month of age. Previous studies have been limited also by the use of intramuscular therapy (rather than via central catheter), which precludes longer treatment duration [7] , and the inclusion of high numbers of patients without proven infection (eg, culture-negative sepsis in neonates) [6, 7] . Some experts discourage OPAT use in young infants, especially for invasive infections such as meningitis [8] . Additional factors that might impose barriers or preclude the use of OPAT in younger infants include the requirement for daily home nursing or clinic visits [9] to monitor disease progression in this population adequately and the lack of data supporting the safety/reliability of the small-caliber central catheters required for young infants. Our study had 2 objectives, to characterize outcomes for a cohort of children <3 months of age treated with OPAT and to compare clinical outcomes among young infants and older pediatric patients.
METHODS

Study Design, Setting, and Population
This was a retrospective cohort study of OPAT use for infants at Primary Children's Hospital (PCH), a 289-bed freestanding children's hospital in Salt Lake City, Utah. PCH is 1 of 22 hospitals in the Intermountain Healthcare system, which operates in Utah and Idaho. All these hospitals share electronic medical records and an enterprise-wide data warehouse, which enables fairly complete capturing of patient outcomes. The study included all infants who were <3 months old at the time of admission to PCH and were discharged with OPAT. The study period was from May 2013 to May 2015. At PCH, we routinely use OPAT to treat young infants with invasive infection by using the same general discharge criteria as those for older children. These criteria include completion of teaching for the caregiver(s) for central line care and ensuring appropriate follow-up care (infectious diseases and primary care) and a suitable home environment, as determined by the medical team. Patients aged <3 months were a subpopulation from a larger prospective study that evaluated an OPAT stewardship intervention for 776 pediatric patients treated with OPAT [10] . During this time period, nearly all infants treated with OPAT were managed by the infectious diseases clinical service at the transition from the hospital to their home [10] . The standard home care model for most patients includes an initial nursing visit on the day of discharge, weekly visits thereafter, and clinic follow-up visits with an infectious diseases specialist. The University of Utah and PCH institutional review boards granted approval for this study.
OPAT Use in Infants Aged <3 Months
We characterized the study population in terms of age in months, length of hospital stay, duration of OPAT use, antimicrobial agents used, and clinical indication for OPAT using descriptive statistics. We also determined the causative pathogen(s) when identifiable on the basis of positive culture results or molecular detection (for enterovirus and herpes simplex virus) from a sample obtained from a normally sterile site such as blood or cerebrospinal fluid. We report these data for a combined cohort and for 2 separate groups (infants ≤30 days of age and infants >30 days of age) ( Table 1) .
Comparison of Clinical Outcomes Between Infants Aged <3 Months and Older Children
The primary clinical outcome was the percentage of patients who experienced a complication defined as an unplanned hospital revisit, either to the emergency department or hospital admission to PCH or any other hospital in the Intermountain Healthcare system. All subsequent encounters during the OPAT course were reviewed to identify OPAT complications and/or disease progression or treatment failure. Encounters that were determined to be unrelated to OPAT or infection were excluded from the primary outcome. OPAT complications included central line thrombosis, dislodgement, infection, and fever. Two of the authors (A. L. H. and J. O.) independently reviewed patient charts and classified the outcomes. Any differences were resolved by informal consensus. We compared the complication rates in infants aged <3 months and those aged ≥3 months by using the Fisher exact test.
RESULTS
During the study period, 53 infants aged <3 months were discharged with OPAT, including 24 (45%) who were ≤30 days of age. Of the 53 infants, 8 (15%) were premature (<37 weeks' gestation). The median age at admission was 32 days (interquartile range [IQR], 23-60 days), and the median hospital length of stay was 4 days (IQR, 4-7 days) ( Table 1 ). After hospital discharge, the patients were treated with OPAT for a median duration of 11 days (IQR, 8-15 days) ( Table 1) , representing a total of 708 OPAT-days. For all the patients, OPAT was administered using a PICC.
OPAT, Clinical Indications, and Antimicrobial Agents
The most common clinical indications for OPAT were bloodstream (37.7%), central nervous system (35.8%), and urinary tract (11.3%) infections (Table 1) . The clinical indications for OPAT were similar in both groups of infants ( Table 1 ). The most commonly used antimicrobial agents were ceftriaxone (34.0%), ampicillin (18.9%), and cefotaxime (15.1%) ( Table 1) .
Causative Pathogens
A presumed causative pathogen was identified in 44 (83%) of 53 patients, including all patients with bloodstream infection and 13 (68%) of 19 patients with central nervous system infections. The most commonly identified organisms were Streptococcus agalactiae (a group B Streptococcus sp) (26.4%), Escherichia coli (18.9%), and Staphylococcus aureus (9.4%) ( Table 1 ). Herpes simplex virus was identified in the cerebrospinal fluid of 2 patients. The causative pathogen was identified in infants aged ≤30 days and in those aged >30 days with similar frequencies (>80% of cases) ( Table 1) .
Clinical Outcomes Among Young Infants and Older Children
During the study period, a total of 5 of 53 patients (9.4% [95% confidence interval [CI], 3.1%-20.6%]) aged <3 months experienced a hospital revisit related to OPAT or their initial infection (Table 1 ). All 5 revisits were classified as catheter-related complications, and none of the patients experienced treatment failure or disease progression (Table 1) . Among these infants, 3 experienced central line thrombosis (2 required line replacement), 1 was evaluated for fever and concern for line infection (culture results were negative), and 1 was evaluated for leaking 
DISCUSSION
We characterized OPAT use after discharge from a freestanding children's hospital for a cohort of infants <3 months of age and compared their clinical outcomes to those of older patients. Among 53 patients aged <3 months, none experienced treatment failure or disease progression, and 9.4% of them experienced a hospital revisit for a catheter-related complication; this percentage is not different from that in older patients and similar to that in other reports [1, 3, 4] . It should be noted that no catheter-related complications were experienced in the 24 infants aged ≤30 days. These findings suggest that OPAT can be considered an appropriate therapeutic option for completing therapy outside of the hospital setting for selected young infants. The advantages of OPAT over prolonged hospitalization include return to daily activities (such as work or school) for caregivers, improved quality of life via return to the home environment, and lower healthcare costs. Over this 2-year study period, OPAT was used for a total of 708 days. Assuming an average daily hospital room cost of $855 (personal communication, J. Olson, unpublished data), at least $600 000 in cost savings was achieved through OPAT use at our institution during the study period compared to that of continued hospitalization.
Routine use of OPAT in young infants can be limited for a variety of reasons. Perhaps the most important limitation is the limited data on safety and effectiveness, especially for the youngest infants (eg, <1 month old). A strength of our study is that nearly all pediatric specialty care in the region takes place within the Intermountain Healthcare system, which shares a comprehensive data warehouse. As a result, we can ascertain our primary clinical outcome with confidence. In addition, more than 80% of the patients had a microbiologically confirmed infection. Our finding that none of the patients, including the infants aged <1 month, experienced disease progression or treatment failure lends support to the effectiveness of our OPAT model in appropriately selected infants. Although the infants included in this study are not directly comparable to the older pediatric patients (ie, they had different conditions [10] ), our results suggest that complication rates are similar in pediatric patients, regardless of patient age and initial diagnosis. The absence of PICC complications in infants aged ≤30 days also suggests that patient age alone should not be a deterrent to using OPAT.
Our study had limitations. The sample size of 53 infants is relatively small, and a larger study could reveal higher complication rates. It is possible that some OPAT complications were not detected if they were minor, did not require intervention, or were managed outside of the acute care setting. Similarly, if the patient sought care outside of the Intermountain Healthcare system, we could not study his or her outcome. In addition, this single-center experience might not be generalizable to other settings. Despite these limitations, our findings suggest that OPAT for young infants can be managed safely and outcomes compare favorably to those of older patients. More widespread use of OPAT in this patient population has the potential to reduce healthcare costs and enhance quality of life for patients and their caregivers. 
